-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascenion portfolio firm sThesis wins up to EUR 1.5 million SPRIND grant for non-invasive hormone sensor tech

PUBT·08/27/2026 08:19:58
Listen to the news
Ascenion portfolio firm sThesis wins up to EUR 1.5 million SPRIND grant for non-invasive hormone sensor tech
  • Ascenion portfolio company sThesis won a SPRIND challenge slot, unlocking up to EUR 1.5 million in non-dilutive funding.
  • The 12-month first phase starts July 2026, targeting a validated proof of concept for continuous, non-invasive hormone sensing.
  • sThesis beat 68 applicants with partners Helmholtz Munich, TUM Klinikum Rechts der Isar, LMU Klinikum.
  • SPRIND’s program offers follow-on tranches of up to EUR 2 million in phase two, up to EUR 2.5 million in phase three.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioM Biotech Cluster Development GmbH published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.